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ABSTRACT 
Background: The association between chronic inflammatory diseases, such as rheumatoid 
arthritis and psoriasis, and insulin resistance (IR) has been well established. Hidradenitis 
suppurativa (HS) is a chronic inflammatory cutaneous disease that affects the apocrine gland-
bearing areas of the body.  
Objective: We aimed to determine the prevalence of IR in patients with HS. 
Methods: This cross-sectional, case-control study enrolled 137 subjects, 76 patients with HS 
and 61 age- and gender-matched controls. Demographic data, clinical examination of HS 
patients, anthropometric measures, cardiovascular risk factors and laboratory studies were 
recorded. The homeostasis model assessment of IR (HOMA-IR) was calculated in all 
participants by measuring fasting plasma glucose and insulin levels.  
Results: The median (IQR) HOMA-IR value in HS patients was significantly higher [2.0 
(1.0-3.6)] than in controls [1.5(0.9-2.3)] (p=0.01). The prevalence of IR was significantly 
higher in cases (43.4%) compared with controls (16.4%) (p=0.001). In the linear regression 
multivariable analysis after adjusting for age, sex and body mass index (BMI), HS remained 
as a significant factor for a higher HOMA-IR [2.51(0.18) vs 1.92(0.21); p=0.04]. The 
HOMA-IR value and the prevalence of IR did not differ significantly among HS patients 
grouped by severity of the disease.  
Conclusion: Our results show an increased frequency of IR in HS. Thus, we suggest  HS 
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INTRODUCTION 
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease of the hair follicle 
characterized by relapsing painful inflammatory nodules, abscesses and fistula tracts in the 
apocrine gland-bearing areas of the body, most commonly in the axillae, inguinal and  
anogenital regions.
1-3 
HS incidence ranges between 4 and 10 cases per 100 000 
population/year and prevalence between 0,2% and 4%.
3 
Although its pathogenesis is not 
completely understood, it is postulated to begin with disturbed keratinization of the follicular 
infundibulum which results in follicular occlusion.
4
 Current knowledge indicates that 
inflammation induced by abnormal immune response plays an important role in the 
pathogenesis of HS.
5
 To this respect, several investigations have shown an increased 
expression of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) and 
interleukin (IL) IL-1β in HS lesions.
6





 levels in HS patients has been reported, suggesting a systemic inflammatory activation 
as a pathogenic mechanism for the disease.  
HS is currently recognized as a systemic inflammatory condition extended beyond the skin, 
and there is an increasing evidence of an association between HS and other comorbidities, 
including cardiovascular (CV) risk factors, inflammatory joint disorders, inflammatory bowel 
disease, endocrinological disorders and psychological disorders.
9-12
 In a recently population-
based cohort study, HS was associated with a significantly increased risk of major adverse 
CV events, including myocardial infarction, ischemic stroke and CV-associated death.
13
 In 
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prevalence of subclinical atherosclerosis in HS patients.
14,15
 Furthermore, HS has also been 
associated with a greater prevalence of CV risk factors, such as diabetes mellitus (DM), 
dyslipidaemia, cigarette smoking, metabolic syndrome (MS) and obesity.
16
 However, it 
should be noted that the premature and accelerated development of atherosclerosis in patients 
with HS is independent of these CV risk factors.
14,15
 This fact suggest that HS itself may be 
an independent risk factor for atherosclerotic CV disease, and that other disease-related 
factors may be implicated in the premature development of the atherogenic process in HS  
patients. 
Insulin resistance (IR) represents the best predictor of type 2 DM and plays a central role in 
the high CV risk of the MS.
17
 The metabolic changes induced by IR may contribute to the 
development of accelerated atherosclerosis and CV disease. This occurs by increasing serum 
glucose and insulin concentrations, but also through mechanisms that involve dyslipidaemia, 
hypertension, and systemic inflammations.
18,19
 In this sense, IR is closely related to the 
presence of a chronic systemic inflammation and has been linked to several chronic 
inflammatory conditions such as rheumatoid arthritis (RA),
20





 Thus, it has also been postulated that IR might to explain the 
increased CV comorbidity associated with these inflammatory diseases. 
Taking all of these considerations into account, the aim of this study was to analyze, for the 
first time to our knowledge, the prevalence of IR in a relatively large, ethnically 
homogeneous cohort of HS patients. Furthermore, we sought to assess whether there is a 
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METHODS 
Study participants and protocol 
This was a cross-sectional, case-control study that included 76 patients with HS and 61 age 
and gender-matched controls. The HS patients were recruited from our Dermatology 
outpatient clinic at the University Hospital Marques de Valdecilla (Santander, Northern 
Spain).  The diagnosis of HS was always done by dermatologists based on clinical findings, 
including a history of recurrent inflamed and non-inflamed nodules, abscesses and sinus 
tracts involving of typical skin areas. The control group consisted of hospital medical staff 
and of subjects who attended the dermatology department due to skin disorders other than 
HS, such as melanocytic nevus, warts or epithelioma. 
The exclusion criteria for both groups were as follows: (a) age<18 years; (b) documented 
history of major adverse cardiovascular events; (c)  type 1 or type 2 DM; (d) chronic kidney 
or liver diseases; (e) diseases that might influence glucose metabolism (such as Cushing 
syndrome, thyroid disorders, polycystic ovary syndrome…); (f) treatment with drugs that 
might affect carbohydrate metabolism (i.e. systemic corticosteroids, retinoids, cyclosporine, 
hypoglycaemic drugs…) in the previous 6 months; and (g) concomitant inflammatory 
disorders, such as cutaneous diseases (psoriasis or atopic dermatitis among others), 
inflammatory bowel disease, inflammatory arthritis (RA or ankylosing spondylitis), or 
autoimmune or connective tissue diseases (scleroderma, SLE…). 
The study protocol was approved by the local institutional ethics committee and all the 
participants provided informed written consent. 
The severity of HS was assessed by the HS Physician Global Assessment (HS-PGA),
24
 
which includes 6 stages (scale 0-5) (Table I). According to HS-PGA and as we have 
previously described in detail,
14
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and as minimal-mild HS (PGA<3). The Hurley grade of disease severity for each zone 
involved at the time of clinical examination was also evaluated. Moreover, information on 
previous treatment for HS was also assessed in all the patients. 
All the participants provided information on their demographic features, past medical 
history, and data on current and prior systemic therapy. Traditional CV risk factors were 
defined as previously reported.
14
 Body height and weight, body mass index (BMI), waist 
circumference (WC), systolic blood pressure (BP) and diastolic BP were measured in all 
patients and controls. BMI was calculated as weight (kg)/ [height (m)]
2
. Blood samples were 
drawn after an overnight fast in all participants, and serum total cholesterol (TC), HDL-c, 
low-density lipoprotein cholesterol (LDL-c), triglycerides, glucose, high-sensitivity C-
reactive protein (hs-CRP) levels and erythrocyte sedimentation rate (ESR) were assessed. 
MS was diagnosed by the presence of three or more criteria according to the National 
Cholesterol Education Program´s Adult Treatment Panel III (ATPIII):
25
 waist circumference 
>102 cm in men or >88 cm in women; hypertriglyceridaemia ≥150 mg/dl or lipid lowering 
treatment;  HDL-c <40 mg/dl in males and <50 mg/dl in females; BP ≥130/85 mm Hg or 
current use of medication for hypertension; fasting plasma glucose ≥110 mg/dl or use of 
antidiabetic drugs.  
The homeostatic model assessment for IR (HOMA-IR) was calculated using this formula: 
fasting insulin level (µIU/ml) x fasting glucose level (mg/dl)/405. IR was defined as an 
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Statistical analysis 
Results were expressed as number (percentage), mean ± standard deviation (SD) or median 
and interquartile range (IQR), as appropriate. Mann-Whitney U-test was performed to 
compare quantitative variables and Chi-square test or Fisher exact test, to compare qualitative 
variables. Multivariable general linear regression models, using HOMA-IR levels as 
dependent variable was performed to assess the relationship between HS and IR. A p value 
<0.05 was considered statistically significant. All the analyses were performed with the Stata 
V.12/SE package (Stata Corp, College Station, Texas, USA). 
 
RESULTS 
A total of 137 participants, 76 patients with HS and 61 control subjects were included in 
the study. Table 2 shows the main demographic, clinical and laboratory findings of patients 
and controls. Patients and controls were similar in age and sex (51% and 49% women, 
respectively, p=0.80). According to HS-PGA, 32 (42.1%) patients were classified as having 
minimal-mild HS (HS-PGA score<3) and the remaining 44 (57.9%) as having moderate-
severe-very severe HS (HS-PGA score≥3). Nineteen HS patients (25%) were classified as 
Hurley stage I, 44 (57.8%) as stage II and 13 (17.1%) as stage III. Twenty-three HS patients 
(30.2%) were on anti-TNF-α agents. 
There was no significant statistical difference between patients and controls in terms of 
height and triglyceride levels. The HS group had significantly higher weight, BMI, waist 
perimeter, systolic and diastolic BP than controls. Moreover, HS group showed lower serum 
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Noteworthy, fasting serum glucose and insulin levels, as well as HOMA-IR values were 
higher in HS patients than in controls (Figure 1). As seen in the table 2, IR, defined as a 
HOMA-IR value greater than 2.5, was observed in 43% of cases and 16 % of controls 
(p=0.001). Besides, the prevalence of MS was 3 times more common in HS patients than in 
control subjects.  
In the general linear regression multivariable analysis after adjusting for age, sex and BMI, 
HS remained as a significant factor for HOMA-IR [mean (SE) 2.51(0.18) vs 1.92(0.21); 
p=0.04]. 
 To determine if the severity of the HS had any impact on the association between HS with 
both IR and MS, we divided the HS patients into two subgroups, according to their HS-PGA 
score (>3 or <3). There was no a significant association between disease severity and the 
prevalence of the MS and/or the HOMA-IR value. Although IR was higher in patients with 
moderate-severe HS (52.3%) than in those with HS-PGA score <3 (31.3%), this difference 
did not reach statistical significance (p=0.06) (Table 3). 
 
DISCUSSION 
The current study shows that patients with HS have a significantly higher prevalence of IR 
compared to age- and sex-matched controls. Moreover, and in accordance with other previous 
reports,
27-29
 we found in our series of HS patients a significantly higher prevalence of MS 
than in the control group. Moreover, patients with HS were more obese and had higher 
prevalence of hyperglycemia, lower HDL-cholesterol levels and raised systolic and diastolic 
BP than control subjects. Nevertheless, no correlation was observed between the severity of 
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    Our results suggest that HS may predispose to the development of IR. In this sense, we 
consider that the high prevalence of obesity found in our HS patients might have influenced 
the obtained results, since it is well-known that obesity can impair the effects of insulin. 
However, even after adjustment for BMI, age and sex, the HOMA-IR value remained 
significantly higher in HS patients than in controls. This fact suggest that HS itself may be an 
independent risk factor for the development of IR. 
    A possible explanation for the link between HS and IR could be the presence of chronic 
inflammation that occurs due to persistent secretion of several pro-inflammatory cytokines, 
such as TNF-α and IL-6.
7,8
  In this regard, TNF-α is considered nowadays one of the major 
pathogenic factors for HS as demonstrated by the efficacy of the anti-TNF-α agent 
adalimumab in the treatment of this disease.
3,24
 Furthermore, it is known that TNF-α plays a 
key role in the impairment in glucose tolerance and insulin sensitivity.
30,31
 Thus, TNF-α is 
able to induce insulin signalling defects by acting on adipocytes and muscle cells, impair 
insulin signalling through inhibition of tyrosine kinase activity of the insulin receptor, and 
suppress the secretion from adipocytes of adiponectin, an anti-inflammatory molecule that 
also regulates insulin sensitivity.
31,32
 To this respect, Malara et al. recently reported that 
patients with HS have significantly decreased the serum adiponectin levels.
33
  
On the other hand, it has been shown that IL-6 induces IR in hepatocytes.
34
 In this scenario, 
the increased inflammatory burden in HS could alter glucose metabolism and induce IR. IR 
may in turn contribute to endothelial dysfunction, leading subsequently to atherosclerosis and 
finally to long-term clinical events, like myocardial infarction or stroke.  
Eddy et al
35
 observed that IR prevention may reduce myocardial infarction risk by 42% in 
young adults. Thus, it is worth emphasizing that several studies have demonstrated a 
beneficial effect of the TNF-α blockade on the mechanisms of accelerated atherogenesis in 
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the effect of these agents on IR.
20,36
 In this regard, it should be noted that about 30% of our 
patients were on adalimumab therapy.  Anti-TNF-α therapy may therefore have improved the 
insulin sensitivity in these patients, underestimating the actual prevalence of IR in HS. On the 
other hand, it is also noteworthy that several studies have shown that metformin, an 
antihyperglycemic agent used for treating type 2 DM, could be beneficial in the treatment of 
HS.
37-38 
Metformin decreases hepatic glucose production and improves insulin sensitivity by 
increasing peripheral glucose uptake and utilization. Although metformin in HS acts by a 
mechanism yet unknown, it has been suggested that the beneficial effects of this drug might 
be, at least in part, through lowering the IR that is present in some patients with HS.
38
  
Our study has the inherent limitations of its cross-sectional design. Despite these 
limitations, we think that it provided important insights into the association of HS and IR that 
may have clinical implications for the overall management of these patients.  
In conclusion, our study provides evidence that patients with HS have a significant higher 
prevalence of IR than controls. There is growing evidence that HS is not only a cutaneous 
disease but a chronic systemic inflammatory disorder with increased CV risk. Thus, it is 
important to control known modifiable CV risk factors according to current guidelines, as 
well as monitoring serum glucose levels in patients with HS. Besides its clinical benefit, 
treatment with anti-TNF-α agents can provide an effective treatment strategy for the 
prevention and control of the development of IR. Nevertheless, further investigations are 
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No abscesses, no draining fistulae, no inflammatory nodules but 
presence of noninflammatory nodules 
Mild 
(score=2) 
No abscesses, no draining fistulae, and 1-4 inflammatory nodules, or 1 
abscess or draining fistula and no inflammatory nodules 
Moderate 
(score=3) 
No abscesses, no draining fistulae and ≥5 inflammatory nodules and ≥1 
inflammatory nodule, or 2-5 abscesses or draining fistula and < 10  
inflammatory nodules  
Severe 
(score=4) 
2-5 abscesses or draining fistula and > 10  inflammatory nodules 
Very severe 
(score=5) 
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Table 2. Demographic, clinical and laboratory findings of patients with HS and controls 
 





Age, y 42.6  11.8 45.6  12.9 0.16 
Height, m  1.67  0.1 1.69  0.1 0.24 
Weight, Kg 82.5  17.9  76.1  16.9 0.04 
BMI, Kg/m
2 
29.3  5.4 26.4  4.5 0.001 
Waist perimeter, cm 99.5  14.1 91.2  13.7 0.001 
SBP, mm Hg 132.3  16.5 124.0  15.9 0.003 
DBP, mm Hg 81.8  13.9 77.0  8.4 0.02 
HDL-c, mg/dl 46.0 (41.0-56.8)   53.0 (46.5-70.0) 0.01 
Triglycerides, mg/dl 96.6  45.2   96.9  66.7 0.97 
Fasting plasma glucose, mg/dl  94.9  13.7 89.1  8.1 0.003 
Fasting plasma insulin, µIU/ml 10.1 (5.4-16.7) 7.3 (4.9-10.7) 0.009 
HOMA-IR 2.0 (1.0-3.6) 1.5 (0.9-2.3) 0.01 
Insulin Resistance, % 43.4 16.4 0.001 
Metabolic Syndrome, % 34.2 11.5 0.002 
 
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; 
HOMA-IR, Homeostatic model assessment for insulin resistance. *Values are expressed as mean  SD or median 
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Table 3. Study parameters in the two HS severity groups. 
Parameter PGA < 3 
(n=32) 
PGA ≥ 3 
(n=44) 
p 
Age, y 39.1  11.6 45.2  11.4 0.03 
Height, m 1.68  0.1 1.67  0.1 0.79 
Weight, Kg 79.6  20.2 84.7  15.9 0.22 
BMI, Kg/m
2 
 28.0  5.5 30.2  5.2 0.08 
Waist perimeter, cm 95.8  15.3 102.1  12.6 0.05 
SBP, mm Hg 130.2  17.4 133.9  15.8 0.33 
DBP, mm Hg 79.0  10.1 83.9  16.0 0.13 
HDL-c, mg/dl 49.5 (42.0-62.0) 45.5 (41.0-55.8) 0.15 
Triglycerides, mg/dl 81.1  37.4 107.8  47.4 0.01 
Fasting plasma glucose, mg/dl 93.8  15.8 95.7  12.2 0.56 
Fasting plasma insulin, µIU/ml 7.1 (1.4-16.9) 11.4 (8.1-16.7) 0.08 
HOMA 1.4 (0.9-3.6) 2.6 (1.2-3.7) 0.17 
Insulin Resistance, % 31.3 52.3 0.06 
Metabolic Syndrome, % 25.0 40.9 0.14 
 
PGA, physician global assessment; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HDL, high-density lipoprotein; HOMA-IR, Homeostatic model assessment for insulin resistance. *Values are expressed as 
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Figure 1. Box plot showing median HOMA-IR values in HS patients and controls. 
 
 
p=0.01 
